StockNews.AI
ZNTL
StockNews.AI
118 days

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

1. Zentalis presented an abstract on azenosertib at ASCO 2025. 2. Azenosertib targets BRAF V600E mutant metastatic colorectal cancer. 3. The drug shows promise in ovarian cancer and other tumors. 4. Clinical trials indicate good tolerance and anti-tumor activity.

5m saved
Insight
Article

FAQ

Why Bullish?

The acceptance of the abstract for presentation at ASCO often correlates with increased investor interest and can lead to a rise in stock price. Previous occurrences in the biotech sector show that positive trial data and scientific presentations tend to drive stock appreciation; thus, ZNTL may see similar trends.

How important is it?

The article discusses azenosertib's potential, which is central to ZNTL's operations. Positive outcomes in ongoing trials and significant presentations can lead to substantial shifts in market sentiment, thus influencing ZNTL's price.

Why Short Term?

The ASCO presentation is imminent, scheduled for late May 2025, which will likely generate immediate market reactions based on the presented data. Historical patterns show that data presented at conferences can influence stock movements shortly thereafter.

Related Companies

BMYAMGNNVDA
April 23, 2025 16:05 ET  | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical data as of an April 4, 2025 data cutoff from the Company’s ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer. Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with previously treated BRAF V600E mutant metastatic colorectal cancer”Abstract Number: 3551Poster Session: Gastrointestinal Cancer – Colorectal and Anal Poster Board: 372Date/Time: Saturday, May 31, 2025, 9:00 a.m. - 12:00 p.m. CDTPresenter: Dr. Jeanne Tie The poster can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website on the day of the presentation. About Azenosertib Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death. About Zentalis Pharmaceuticals Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego. For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.  Contact: Haibo Wang - Chief Business OfficerRon Moldaver - Investor Relationsir@zentalis.com  

Related News